Core Points - Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing products for chronic wound management, infertility, and cosmeceuticals for health and beauty [1][6] - The company will present at the Skyline Signature Series™ on October 8, 2025, at 11:00 AM ET, allowing investors to engage in real-time Q&A [1][2][3] Event Details - Event Name: Skyline Signature Series™ [3] - Date: October 8, 2025 [3] - Time: 11:00 AM ET [3] - Registration Link: https://us02web.zoom.us/webinar/register/WN_wWWf2nr8QZmKgzx7IaKrXA/registration [3] About Skyline Corporate Communications Group - Skyline Corporate Communications Group, LLC provides investor relations services and ensures a high-quality audience for public companies through careful vetting [4][5] - The firm has experience in strategic messaging and investor communications for public corporations across various industries [5]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 空间转录组学技术 的发明，彻底改变了生物医学研究，使我们能够以空间分辨率对细胞和组织中的基因活 动进行分析。这些工具已在各种组织和情境中得到广泛应用，为细胞身份、相互作用和组织结构提供了前 所未有的见解，揭示了健康和疾病中的关键分子机制。 现有的 空间转录组学技术 大致可分为两类：1）空间捕获/标记技术，利用高通量测序读取空间标记的转录 本；2）基于图像的技术，利用多重荧光原位杂交 （FISH） 或原位测序 （ISS） 直接检测空间转录本。然 而，这两类方法都存在 " 鱼与熊掌不可兼得 "的困境——前者可实现 全基因组转录本覆盖，但 空间分辨率 较低，且不能保留细胞和亚细胞形态；后者可实现 单分子的空间分辨率，并能保持细胞和亚细胞形态，但 转录组覆盖率低 。 这阻碍了在精细空间尺度上进行无偏倚的全局性转录组分析。 2025 年 10 月 1 日， 耶鲁大学 王思远 团队 （博士后 程育宝 、 党盛源 、 张源 作为共同第一作者 ） 在 国际顶尖学术期刊 Cell 上发表了题为： Sequencing-free whole-genome spatial transcrip ...

编辑丨王多鱼 排版丨水成文 尽管前体信使 RNA （pre-mRNA） 外显子的反向剪接是由经典的剪接体机制进行的低效加工，但这种反向剪接会在全基因组范围内产生 环状 RNA （circRNA） ，其序列与来自相同基因位点的线性 RNA 几乎完全相同，只是在反向剪接连接 （BSJ） 位点有所不同。 重要的是，越来越多的证据表明，一些 circRNA 通过不同的分子作用模式在基因表达调控中发挥着重要作用。这些作用包括调节转录、干扰 mRNA 剪接、作 为"海绵"吸附 miRNA 或蛋白质、影响翻译以及被翻译为多肽。一些高表达的 circRNA 已被证实参与维持静止的造血干细胞、调控细胞生长和癌症进展、影响大 脑功能和神经元发育以及调控先天免疫反应。 这些发现增加了人类转录组的复杂性和多样性。 此外， 可变环化 （ alternative circularization， AC） 导致 单个基因位点产生多个 circRNA，这 进一步扩大了 circ RN A 的功能复杂性，造就了不同细胞系和 组织中 circRNA 表达的独特图谱。然而，大多数通过可变环化产生的 circRNA 的功能，仍然未知。 在这项新研究 ...

Disciplinary Actions by Companies - Multiple employers across the U.S. have taken disciplinary actions, including terminations, against employees who made inappropriate comments regarding the assassination of Charlie Kirk [1][4][5] - Nasdaq terminated an employee for social media posts that violated its zero-tolerance policy on violence [4] - The Broad Institute fired an employee for posting a "deeply offensive" comment about Kirk's killing [5] - Perkins Coie dismissed a lawyer for criticizing Kirk on social media, stating the comments did not reflect the firm's views [6][7] - Office Depot fired an employee after a viral video showed staff refusing to print posters for a vigil for Kirk [8][9] - The Joe Burrow Foundation terminated an advisory board member for making inappropriate remarks following Kirk's assassination [10] - MSNBC political analyst Matthew Dowd was fired after making comments about the divisive nature of Kirk's rhetoric [12] - The Carolina Panthers fired a communications department employee for social media posts questioning public mourning for Kirk [13][14] - The West Ada School District dismissed a cheerleading coach for allegedly celebrating Kirk's death in a video [16]

PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan's strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the SomaScan™ 11K Assay to run 100,000 plasma samples from the PRECISE-SG100K bioba ...

Core Viewpoint - The article discusses a groundbreaking research published in the journal Cell, which introduces a novel framework called Cell Behavior Hypothesis Grammar. This framework allows researchers to use natural language to model complex multicellular systems, facilitating virtual cell laboratories for accelerated research in cancer and neuroscience [3][4][19]. Group 1: Research Framework - The Cell Behavior Hypothesis Grammar enables the construction of mathematical models using natural language descriptions of cellular rules, integrating biological knowledge and multi-omics data to create virtual cell models for thought experiments [4][10]. - This framework allows researchers to predict multicellular emergent behaviors and test new hypotheses, showcasing its potential in understanding cancer metastasis and drug resistance [4][19]. Group 2: Applications in Cancer Research - In cancer research, simulations revealed that cancer-associated fibroblasts (CAFs) can induce cancer cell shape changes, accelerating metastasis, while high-density CAFs can create physical barriers to cancer cell escape [13]. - During immune therapy simulations, it was found that macrophages could "betray" by secreting EGF signals that enhance breast cancer cell migration, leading to a 75% reduction in metastasis when EGF receptors were blocked [14]. Group 3: Applications in Neuroscience - The research team successfully simulated brain development, demonstrating how stem cells undergo asymmetric division to form different cortical layers, accurately replicating the differences between sensory and auditory cortices using data from the Allen Brain Atlas [16]. Group 4: Virtual Clinical Trials - The model initialized with pancreatic cancer patient data tested various immunotherapy combinations, revealing that tumors with high macrophage content responded best to a triplet therapy, paving the way for personalized treatment approaches [18]. Group 5: Future Implications - The open-source nature of the Cell Behavior Hypothesis Grammar allows researchers to quickly test drug regimens, potentially reducing drug development timelines from ten years to a single night in front of a computer screen [21].

Core Viewpoint - iSpecimen Inc. has announced a public offering of 5,714,283 shares at a price of $0.70 per share, aiming to raise approximately $4 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering is priced at $0.70 per share, with expected gross proceeds of around $4 million [1]. - The offering is set to close on July 25, 2025, pending customary closing conditions [1]. - WestPark Capital, Inc. is acting as the Sole Book-Runner for the offering [2]. Group 2: Use of Proceeds - The company plans to allocate $1,500,000 for marketing and advertising services from IR Agency LLC [2]. - An initial milestone payment of $1,000,000 will be made to Sales Stack Solutions Corp. [2]. - Remaining funds will be used for working capital and general corporate purposes [2]. Group 3: Company Overview - iSpecimen operates an online marketplace connecting scientists with healthcare specimen providers for medical research [5]. - The company utilizes proprietary cloud-based technology to facilitate searches for biospecimens across a network of healthcare organizations [5].

Company Announcement - Standard BioTools Inc. will report its second quarter 2025 financial results on August 11, 2025, after market close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET to discuss the financial results and operational progress [1] Access Information - Individuals can access the conference call by dialing US domestic callers: (888) 346-3970 and outside US callers: (412) 902-4297 [1] - Live audio of the webcast will be available on the Investor Relations page of the company's website and will be archived for later access [2] Company Overview - Standard BioTools Inc. is a leading provider of next-generation technologies that assist biomedical researchers in developing better medicines more efficiently [3] - The company utilizes proprietary technologies such as SomaScan, mass cytometry, and microfluidics to provide insights in health and disease, focusing on oncology, immunology, and immunotherapy [3] - Standard BioTools collaborates with various entities including academic, government, pharmaceutical, and clinical laboratories globally [3]

Core Viewpoint - Cuprina Holdings is advancing its research on collagen peptides derived from American bullfrog skin, aiming to develop products for chronic wound management, infertility, and the cosmeceutical sector, with significant potential for commercial applications and market growth [1][8]. Group 1: Research Collaborations - The first study, a consultancy proposal with Republic Polytechnic, focused on generating bullfrog collagen peptides for sale as individual fragments or as a whole [2]. - The second study, a research collaboration with the National University of Singapore, aims to explore the use of bullfrog collagen peptides in 3D printable wound care dressings, supported by national funding [4]. - The third study, with the Singapore Institute of Technology, seeks to produce a superior powdered form of bullfrog collagen peptides for cosmeceutical applications [6]. Group 2: Product Development and Applications - Cuprina has identified methods to generate peptides for cosmeceutical applications, including skin moisturization and collagen remodeling, and is pursuing marketing opportunities with cosmeceutical companies [3]. - Testing is underway to integrate bullfrog collagen into microneedling patches, which could enhance wound healing by controlling inflammation [5]. - In vivo and in vitro tests have shown that bullfrog collagen exhibits superior properties, achieving 90% wound closure in 24 hours compared to 34% for bovine collagen [7]. Group 3: Market Potential - The global collagen peptides market is projected to grow from US$699 million in 2023 to US$922 million in 2028, reflecting a CAGR of 5.7%, driven by increased utilization across various sectors [8].

Group 1 - The article discusses the rapid advancement of AI in the fields of science and biomedicine, particularly focusing on the emergence of AI scientist agents that can autonomously conduct research and drug discovery [3][4]. - AI scientist agents are defined as agentic systems that can autonomously propose hypotheses, design experiments, and iteratively refine their approaches, distinguishing them from general-purpose agents [4][19]. - The development of Biomni, a biomedical agent environment, aims to integrate various tools, databases, and software to facilitate autonomous research tasks across different biomedical subfields [4][34][38]. Group 2 - FutureHouse, an AI lab backed by former Google CEO Eric Schmidt, has developed AI scientist agents that have reportedly discovered new drugs, showcasing the potential of AI in drug development [3][22][25]. - The article emphasizes that while general-purpose agents like OpenAI's Deep Research can perform many research tasks, they lack the specialized environment and expert knowledge necessary to fully function as AI scientists [28][29]. - The Biomni project aims to create a flexible environment that allows AI agents to perform a wide range of biomedical research tasks, addressing the challenge of integrating numerous specialized tools and databases [34][38][42]. Group 3 - The article highlights the importance of designing benchmarks for AI in biology, as the field currently lacks standardized metrics similar to those in other domains like image recognition [70]. - AI scientist agents are expected to automate routine tasks and potentially exceed human capabilities in specific areas, such as rare disease diagnosis, by leveraging their ability to process large datasets [30][31]. - The integration of AI tools like AlphaFold into the workflows of AI scientists is seen as a way to enhance their capabilities in protein design and other biological tasks [53][54].